PortalPublikationenProfiling circulating tumour cells and other biomarkers of i...

Profiling circulating tumour cells and other biomarkers of invasive cancers

Standard

Profiling circulating tumour cells and other biomarkers of invasive cancers. / Poudineh, Mahla; Sargent, Edward H; Pantel, Klaus; Kelley, Shana O.

in: NAT BIOMED ENG, Jahrgang 2, Nr. 2, 02.2018, S. 72-84.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Poudineh, M, Sargent, EH, Pantel, K & Kelley, SO 2018, 'Profiling circulating tumour cells and other biomarkers of invasive cancers', NAT BIOMED ENG, Jg. 2, Nr. 2, S. 72-84. https://doi.org/10.1038/s41551-018-0190-5

APA

Poudineh, M., Sargent, E. H., Pantel, K., & Kelley, S. O. (2018). Profiling circulating tumour cells and other biomarkers of invasive cancers. NAT BIOMED ENG, 2(2), 72-84. https://doi.org/10.1038/s41551-018-0190-5

Vancouver

Poudineh M, Sargent EH, Pantel K, Kelley SO. Profiling circulating tumour cells and other biomarkers of invasive cancers. NAT BIOMED ENG. 2018 Feb;2(2):72-84. https://doi.org/10.1038/s41551-018-0190-5

Bibtex

@article{bdcba2748c15434090e8474d9c505269,
title = "Profiling circulating tumour cells and other biomarkers of invasive cancers",
abstract = "During cancer progression, many tumours shed circulating tumour cells (CTCs) and other biomarkers into the bloodstream. The analysis of CTCs offers the prospect of collecting a liquid biopsy from a patient's blood to predict and monitor therapeutic responses and tumour recurrence. In this Review, we discuss progress towards the isolation and recovery of bulk CTCs from whole blood samples for the identification of cells with high metastatic potential. We provide an overview of the techniques that initially pointed to the clinical significance of CTCs and describe the key requirements for clinical applications of CTC analysis. We also summarize recent advances that permit the functional and biochemical phenotypes of CTCs to be characterized, and discuss the potential roles of these CTC characteristics in the formation of metastatic lesions. Moreover, we discuss the use of circulating tumour DNA and exosomes as markers for early cancer diagnosis and for the monitoring of cancer progression. Next-generation technologies and biomarkers for invasive cancers should allow for the unequivocal determination of the metastatic potential of CTCs, and for the meaningful analysis of circulating tumour DNA and exosomes.",
author = "Mahla Poudineh and Sargent, {Edward H} and Klaus Pantel and Kelley, {Shana O}",
year = "2018",
month = feb,
doi = "10.1038/s41551-018-0190-5",
language = "English",
volume = "2",
pages = "72--84",
journal = "NAT BIOMED ENG",
issn = "2157-846X",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Profiling circulating tumour cells and other biomarkers of invasive cancers

AU - Poudineh, Mahla

AU - Sargent, Edward H

AU - Pantel, Klaus

AU - Kelley, Shana O

PY - 2018/2

Y1 - 2018/2

N2 - During cancer progression, many tumours shed circulating tumour cells (CTCs) and other biomarkers into the bloodstream. The analysis of CTCs offers the prospect of collecting a liquid biopsy from a patient's blood to predict and monitor therapeutic responses and tumour recurrence. In this Review, we discuss progress towards the isolation and recovery of bulk CTCs from whole blood samples for the identification of cells with high metastatic potential. We provide an overview of the techniques that initially pointed to the clinical significance of CTCs and describe the key requirements for clinical applications of CTC analysis. We also summarize recent advances that permit the functional and biochemical phenotypes of CTCs to be characterized, and discuss the potential roles of these CTC characteristics in the formation of metastatic lesions. Moreover, we discuss the use of circulating tumour DNA and exosomes as markers for early cancer diagnosis and for the monitoring of cancer progression. Next-generation technologies and biomarkers for invasive cancers should allow for the unequivocal determination of the metastatic potential of CTCs, and for the meaningful analysis of circulating tumour DNA and exosomes.

AB - During cancer progression, many tumours shed circulating tumour cells (CTCs) and other biomarkers into the bloodstream. The analysis of CTCs offers the prospect of collecting a liquid biopsy from a patient's blood to predict and monitor therapeutic responses and tumour recurrence. In this Review, we discuss progress towards the isolation and recovery of bulk CTCs from whole blood samples for the identification of cells with high metastatic potential. We provide an overview of the techniques that initially pointed to the clinical significance of CTCs and describe the key requirements for clinical applications of CTC analysis. We also summarize recent advances that permit the functional and biochemical phenotypes of CTCs to be characterized, and discuss the potential roles of these CTC characteristics in the formation of metastatic lesions. Moreover, we discuss the use of circulating tumour DNA and exosomes as markers for early cancer diagnosis and for the monitoring of cancer progression. Next-generation technologies and biomarkers for invasive cancers should allow for the unequivocal determination of the metastatic potential of CTCs, and for the meaningful analysis of circulating tumour DNA and exosomes.

U2 - 10.1038/s41551-018-0190-5

DO - 10.1038/s41551-018-0190-5

M3 - SCORING: Review article

C2 - 31015625

VL - 2

SP - 72

EP - 84

JO - NAT BIOMED ENG

JF - NAT BIOMED ENG

SN - 2157-846X

IS - 2

ER -